Concepedia

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

Wanjun Tao, Jia Yang, Yongxian Jiang, Wenwen Chen, Yixin Wang

Dose-Response · 2020 · 14 citations · 12 references

DOIFull text

Open access

Abstract

Addition of bevacizumab increases the treatment response of paclitaxel and carboplatin chemotherapy and overall survival of women with advanced cervical cancers, but it is not well tolerated.

References

12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 86.6K citations · Full text

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 656 citations · Full text

, , +11

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505

Ryo Kitagawa, Noriyuki Katsumata, Taro Shibata et al. · Journal of Clinical Oncology · 2015 · 382 citations · Full text